ArticleMolecular medicine (Cambridge, Mass.)2022

Novel eIF4A1 inhibitors with anti-tumor activity in lymphoma.

Forum Kayastha et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.